UF startup DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced that data from the Phase 1 study of DNX-2401 in diffuse intrinsic pontine glioma (DIPG) was presented in an oral presentation at the 26th Annual Meeting and Education Day of the Society for Neuro-oncology (SNO), which was held from November 18-21, 2021 in Boston, MA. DNX-2401 is an adenovirus-based immunotherapy that is engineered to selectively kill tumor cells and trigger a robust anti-tumor immune response. It has received FDA Fast Track and Rare Pediatric Disease designations for DIPG.
“DIPG is a rapidly progressing tumor with the worst prognosis of any pediatric cancer,” said Jeffrey Knapp, chief executive officer of DNAtrix. “Patients receiving conventional radiation therapy typically have a median overall survival of between eight and eleven months, with less than ten percent of the patients reaching the two-year survival mark. The preliminary overall survival data from the DNX-2401 Phase 1 study show a median survival of close to 18 months, with three patients still in follow-up. This is a significant and remarkable impact on overall survival in this difficult-to-treat tumor type, and we look forward to completing the study.”Learn more about DNAtrix Announces Oral Presentation of Positive Overall Survival Data With DNX-2401 in DIPG at the Society for Neuro-Oncology (SNO) Annual Meeting.